Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$468.63 USD

468.63
827,133

-9.21 (-1.93%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $468.63 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IDEXX (IDXX) Earnings Beat Estimates in Q3, Margins Rise

by Zacks Equity Research

IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.

Idexx Laboratories (IDXX) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 19.01% and 7.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Can Diagnostics Aid Hologic (HOLX) Q4 Sales Amid Coronavirus?

by Zacks Equity Research

Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the fourth quarter of fiscal 2020 amid the coronavirus-led economic doldrums.

Owens & Minor (OMI) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Owens & Minor's (OMI) PPE sales are likely to have maintained its momentum during Q3, thus driving the top line.

STERIS (STE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) third-quarter results benefit from solid segmental performance.

Quidel (QDEL) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Quidel's (QDEL) fiscal third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.

Trina Mukherjee headshot

Medical Products' Oct 29 Earnings Roster: SYK, BAX & More

by Trina Mukherjee

Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.

Varian (VAR) Earnings and Revenues Surpass Estimates in Q4

by Zacks Equity Research

Varian's (VAR) receipt of 10 Ethos orders in Q4 instills optimism

Why IDEXX Laboratories (IDXX) Might Surprise This Earnings Season

by Zacks Equity Research

IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q3.

LabCorp (LH) Q3 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

LabCorp (LH) Diagnostics business in Q3 grows significantly on organic volume improvements as a result of growing demand for COVID-19 testing.

ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results

Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.

Ecolab (ECL) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

Although Ecolab's (ECL) third-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.

NextGen Healthcare (NXGN) Gains 8.1% Post Q2 Earnings Beat

by Zacks Equity Research

NextGen (NXGN) benefited from both its operating segments in Q2.

Mark Vickery headshot

Top Research Reports for AMD, Workday & Moody's

by Mark Vickery

Today's Research Daily features new research reports on 12 major stocks, including Advanced Micro Devices (AMD), Workday (WDAY) and Moody's (MCO).

What's in Store for IDEXX Laboratories (IDXX) in Q3 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) third-quarter top line is likely to have benefited from strength in CAG and LPD businesses.

Illumina (ILMN) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.

Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Bio-Rad (BIO) Q3 earnings are expected to have benefited from strong sales particularly within core PCR products, Droplet Digital PCR and Process Media.

Boston Scientific (BSX) Q3 Earnings to Grow on Vital Procedures

by Zacks Equity Research

Boston Scientific's (BSX) Q3 sales are expected to have benefited from growing demand for less-deferrable procedures across most of the segments.

Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics' (DGX) Q3 Earnings Beat, Base Volume Rises

by Zacks Equity Research

In Q3, Quest Diagnostics (DGX) sees strong signs of the health care system returning to pre-pandemic levels